US Dollar: Pressure builds as risk premia rise – ABN AMRO
ABN AMRO’s Georgette Boele notes that sentiment towards the Dollar is weakening as fiscal concerns and rising risk premia outweigh the support from higher US Treasury yields. The Treasury’s expanded buyback programme has failed to reassure investors, who remain focused on US debt dynamics and fiscal risks.
Dollar pressured by debt concerns
"Even before the announcement, the US dollar was struggling despite higher US Treasury yields, as investors were concerned about fiscal deficits and rising risk premia."
"After the announcement, US Treasury yields fell and the US dollar came under even more pressure across the board."
"The euro has benefited from this dollar weakness and is likely to continue doing so if the dollar falls further."
"In this environment, the risk premium appears to be a more important driver of the US dollar than nominal yields."
"Indeed, since the start of July, the US term premium has been on an upward trend, while the US dollar has moved lower."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The second wave of energy price increases is looming! European Central Bank’s Lane warns: eurozone inflation will be higher and more persistent
Philip Lane, Chief Economist of the European Central Bank, stated that a new round of high energy prices means inflation in the eurozone will remain elevated for longer than the ECB initially anticipated.
Bitcoin Trades Around $86K as FOMO Hits Highest Level Since 2024

siRNA rising star ADARx (ADRX.US) launches $350 millions IPO, AbbVie subscribes to 4.9% of shares with a maximum investment of $100 millions
ADARx plans to raise $350 millions and list on Nasdaq. AbbVie will invest up to $100 millions to acquire a 4.9% stake, with a median valuation of $1.8 billions.
Roche (RHHBY.US) weight loss injection shows positive mid-term trial results: average weight loss of 15.5% over 48 weeks, blood sugar levels drop by 2.65%.
The experimental weight-loss injection enicepatide simultaneously lowered blood sugar and body weight in overweight or obese patients with type 2 diabetes during a mid-stage clinical trial.
